Intellectual Property India Publishes Patent Application for Use Of Tpl2 Inhibitors, Such As A Prodrug Of Tilpisertib, To Treat Inflammatory Bowel Disease Or Ulcerative Colitis

MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202617064207 A) filed by Gilead Sciences, Inc. on May 21, 2026, for Use Of Tpl2 Inhibitors, Such As A Prodrug Of Tilpisertib, To Treat Inflammatory Bowel Disease Or Ulcerative Colitis.

Inventors include Weber, Elijah J.; Othman, Ahmed A.; Chang, Ingrid J.; and Mckevitt, Matthew T..

The application for the patent was published on June 26, 2026, under issue no. 26/2026.

Abstract: The present disclosure relates generally to methods of using inhibitors of tumor progression locus 2 (TPL2) kinase for treating, stabilizing, or lessening the severity or progression of inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), and pharmaceutical compositions including TPL2 kinase inhibitors for use in such methods.

Disclaimer: Curated by HT Syndication.